Resalis Therapeutics
Luca Borgio serves as the Head of Operations at Resalis Therapeutics, overseeing drug development activities for ASO/RNA-based therapies targeting metabolic diseases and oncology. With extensive experience in project, program, and portfolio management, Borgio has successfully coordinated cross-functional teams, managed asset life-cycles, and collaborated with regulatory affairs to advance development pipelines. Prior roles include Global Development Programme Manager at Zambon, IT Director at seQure Life Sciences, and Project Manager at Aptuit, among others, demonstrating a robust background in drug discovery, clinical development, and operational leadership. Luca holds an MBA from IE Business School and multiple degrees in bioengineering and biological sciences.
This person is not in any teams
Resalis Therapeutics
1 followers
Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.